866-997-4948(US-Canada Toll Free)

Leiomyosarcoma - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 144 Pages

Leiomyosarcoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma Pipeline Review, H1 2017, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leiomyosarcoma Overview
Leiomyosarcoma Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Leiomyosarcoma Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leiomyosarcoma Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
BeiGene Ltd
Cell Medica Ltd
Karyopharm Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Novartis AG
Pfizer Inc
Vicore Pharma AB
Yooyoung Pharmaceutical Co Ltd
Leiomyosarcoma Drug Profiles
AL-3818 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avelumab Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axitinib Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baltaleucel-T Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-290 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mocetinostat Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Leiomyosarcoma Dormant Projects
Leiomyosarcoma Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Leiomyosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Leiomyosarcoma Pipeline by Advenchen Laboratories LLC, H1 2017
Leiomyosarcoma Pipeline by BeiGene Ltd, H1 2017
Leiomyosarcoma Pipeline by Cell Medica Ltd, H1 2017
Leiomyosarcoma Pipeline by Karyopharm Therapeutics Inc, H1 2017
Leiomyosarcoma Pipeline by Merck & Co Inc, H1 2017
Leiomyosarcoma Pipeline by Merck KGaA, H1 2017
Leiomyosarcoma Pipeline by Mirati Therapeutics Inc, H1 2017
Leiomyosarcoma Pipeline by Novartis AG, H1 2017
Leiomyosarcoma Pipeline by Pfizer Inc, H1 2017
Leiomyosarcoma Pipeline by Vicore Pharma AB, H1 2017
Leiomyosarcoma Pipeline by Yooyoung Pharmaceutical Co Ltd, H1 2017
Leiomyosarcoma Dormant Projects, H1 2017
Leiomyosarcoma Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Leiomyosarcoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *